Title:
CAN LUMACAFTOR-IVACAFTOR TREATMENT IMPROVE CYSTIC FIBROSIS RELATED DIABETES?

Authors:
Bastien Misgault\textsuperscript{a}, Eva Chatron\textsuperscript{b}, Quitterie Reynaud\textsuperscript{c}, Sandrine Touzet\textsuperscript{d}, Michel Abely\textsuperscript{e}, Laurent Melly\textsuperscript{f}, Stéphane Dominique\textsuperscript{g}, Françoise Troussier\textsuperscript{h}, Olivia Ronson-Pradel\textsuperscript{i}, Michèle Gerardin\textsuperscript{j}, Julie Mankikian\textsuperscript{k}, Laure Cosson\textsuperscript{l}, Raphaël Chiron\textsuperscript{m}, Leila Bounyar\textsuperscript{n}, Michel Porzio\textsuperscript{o}, Isabelle Durieu\textsuperscript{i}, Laurence Weiss\textsuperscript{n}, Romain Kessler\textsuperscript{b,o}, and Laurence Kessler\textsuperscript{a,o}

Affiliations:
aService d'endocrinologie, diabète et nutrition, Hôpitaux Universitaires de Strasbourg, place de l'hôpital, 67091 Strasbourg, France
bService de pneumologie et CRCM adulte, Hôpitaux Universitaires de Strasbourg, 1 place de l'hôpital, 67091 Strasbourg, France
cDépartement de Internal Medicine Adult Cystic Fibrosis Care Center, Hospices Civils de Lyon, Lyon, France; EA HESPER 7425, Université Claude Bernard Lyon 1, France.
dPôle de Santé Publique, Hospices Civils de Lyon, Lyon, France; EA HESPER 7425, Université Claude Bernard Lyon 1, France
eCRCM, Hôpitaux Universitaires de Reims, 47, rue Cognacq-Jay, 51092 Reims, France
fCentre de Giens, Hospices Civils de Lyon, France
gCRCM, CHU Rouen, France
hCRCM Angers-Le Mans, CHU Angers, France
iCRCM, CHU Marseille, France
jCRCM enfant, Hôpital Robert Debré, Paris, France
kCRCM, Hôpital Bretonneau, CHRU Tours, France
lCRCM, Hôpital de Clocheville, CHRU Tours, France
mCRCM, Raphael Chiron, Hôpital Arnaud de Villeneuve, Montpellier, France
nCRCM pédiatrique, Hôpitaux Universitaires de Strasbourg, 1 Avenue Molière, 67098 Strasbourg, France
oInserm UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle, Université de Strasbourg

What was your research question?
Will CFTR modulators delay the onset of diabetes or will prevent or treat diabetes in CF?

Why is this important?
Cystic Fibrosis Research News

Life expectancy of people with CF has dramatically increased and currently extends to over 50 years. This lengthening of life expectancy is accompanied by the emergence of new aspects of the disease, especially diabetes. CF-related diabetes (CFRD) represents one of the most frequent complications of CF. Currently, diabetes is present in about 15-20% of the adolescents and in 50% of the adults with CF. Its prevalence is expected to increase with the improvement of survival. CFRD is associated with worse clinical outcomes like a higher pulmonary exacerbation rate and a faster decline of lung function.

What did you do?
We have conducted a clinical observational multicenter study involving ten French CF centers. We evaluated the impact of one-year lumacaftor-ivacaftor treatment, a combination of CFTR modulators. We observed the impact in pre-diabetic people with CF having blood sugar levels above the normal range, but not high enough to be diagnosed as having overt diabetes) and people with CF having a CFRD diagnosed with oral glucose tolerance test.

What did you find?
At the start of the study, 78% of the participants were pre-diabetic and 22% had newly diagnosed CFRD. Metabolic status improved, after one-year of modulator treatment, 50% of the participants was free of CFRD, 40% was pre-diabetic and 10% remained diabetic. We observed also an improvement in respiratory function with an increase in body weight. Furthermore, a decrease in percentage of people who received at least one intravenous antibiotic course per/year was reported. These findings are in line with previous clinical trials.

What does this mean and reasons for caution?
These positive results must be tempered by the non-randomized design of our study. However, since beneficial lumacaftor-ivacaftor treatment effects have convincingly been demonstrated in people with CF, randomization with a placebo would have been unethical. As such, we conducted this observational, prospective study, including only people with CF who did not use CFTR modulators before. The strength of our study is that it was performed in a real-world setting.

What’s next?
In conclusion, we demonstrated a positive impact of lumacaftor-ivacaftor on pre-diabetes or newly diagnosed CFRD in people with CF. Larger studies are needed to confirm our results and to evaluate other combinations of CFTR modulators.

Original manuscript citation in PubMed